amifostine anhydrous has been researched along with Endometrial Neoplasms in 5 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Radiation colitis was assessed by clinical, endoscopic and histolopathological criteria." | 2.75 | Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis. ( Bai, M; Batistatou, A; Briasoulis, E; Capizzello, A; Christodoulou, D; Karavasilis, V; Katsanos, KH; Panelos, I; Tolis, C; Tsekeris, P; Tsianos, EV, 2010) |
| "Among the poor-outcome endometrial cancers, there is a high frequency of TP53 mutations." | 1.36 | Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent. ( Beck, BB; Dai, D; Elmaoued, R; Fischer, E; Leslie, KK; Luo, W; Meng, X; Wu, F, 2010) |
| "Paclitaxel IC50 value was reduced from 14 to 2 nmol/L with pretreatment of a single dose of 178 micromol/L of amifostine for 72 hours." | 1.33 | A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. ( Dai, D; Davies, S; Holmes, AM; Leslie, KK; Nguyen, T; Theele, DP; Verschraegen, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katsanos, KH | 1 |
| Briasoulis, E | 1 |
| Tsekeris, P | 1 |
| Batistatou, A | 1 |
| Bai, M | 1 |
| Tolis, C | 1 |
| Capizzello, A | 1 |
| Panelos, I | 1 |
| Karavasilis, V | 1 |
| Christodoulou, D | 1 |
| Tsianos, EV | 1 |
| Luo, W | 1 |
| Wu, F | 1 |
| Elmaoued, R | 1 |
| Beck, BB | 1 |
| Fischer, E | 1 |
| Meng, X | 1 |
| Leslie, KK | 2 |
| Dai, D | 2 |
| Kouvaris, J | 1 |
| Kouloulias, V | 1 |
| Malas, E | 1 |
| Antypas, C | 1 |
| Kokakis, J | 1 |
| Michopoulos, S | 1 |
| Matsopoulos, G | 1 |
| Vlahos, L | 1 |
| Scudder, SA | 1 |
| Liu, PY | 1 |
| Wilczynski, SP | 1 |
| Smith, HO | 1 |
| Jiang, C | 1 |
| Hallum, AV | 1 |
| Smith, GB | 1 |
| Hannigan, EV | 1 |
| Markman, M | 1 |
| Alberts, DS | 1 |
| Holmes, AM | 1 |
| Nguyen, T | 1 |
| Davies, S | 1 |
| Theele, DP | 1 |
| Verschraegen, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma[NCT00003127] | Phase 2 | 57 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for amifostine anhydrous and Endometrial Neoplasms
| Article | Year |
|---|---|
Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.
Topics: Adult; Aged; Amifostine; Colitis; Combined Modality Therapy; Endometrial Neoplasms; Female; Follow-U | 2010 |
Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Topics: Aged; Amifostine; Chi-Square Distribution; Data Interpretation, Statistical; Endometrial Neoplasms; | 2003 |
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
2 other studies available for amifostine anhydrous and Endometrial Neoplasms
| Article | Year |
|---|---|
Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; C | 2010 |
A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processe | 2005 |